Amgen Inc. FY 2025 10-K, explained in plain English
Key financials — as reported
| Total revenue | $36.8B |
| Gross margin | 67.2% |
| Operating income | $9.1B |
| Net income | $7.7B |
| Diluted EPS | $14.23 |
| Cash & equivalents | $9.1B |
| Total assets | $90.6B |
| Long-term debt | $54.6B |
Key takeaway
Amgen posted $36.75 billion in revenue and $7.71 billion net income for fiscal 2025, with a 14.1% effective tax rate well below the 21% statutory rate due to foreign and research tax credits.
🔒 4 more takeaways in the full analysis
Beneath the surface
Long-term debt of $54.6 billion dwarfs cash and marketable securities of roughly $17.7 billion (cash $9.13B plus available-for-sale securities $8.53B), indicating a substantial net debt position despite investment-grade ratings.
🔒 3 more insights a headline reader would miss
This is the free preview. The full analysis explains every line item above and includes 7 more findings — plus insider trades, activist stakes, and 8-K events for AMGN.
Read the full analysis free Free account · 5 full analyses included · no card required